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• It’s unclear whether there is SBP threshold impacting on CVD inpatient costs and 
could be altered by peer-support in people with diabetes  
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• A novel two-part model revealed the combined peer-support intervention altered the 
above association 
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TITLE: Association between systolic blood pressure and cardiovascular inpatient cost 1 
moderated by peer-support intervention among type 2 diabetes: two cohorts study 2 
ABSTRACT 3 
 4 
Objective 5 
People with type 2 diabetes and increased systolic blood pressure (SBP) are at high risk of 6 
cardiovascular diseases (CVD). We aimed to investigate the association between CVD 7 
related hospital payments and SBP and test whether it is influenced by diabetes peer-8 
support. 9 
 10 
Methods 11 
Two cohorts comprising people with type 2 diabetes were included.  The first cohort includes 12 
4,704 patients with type 2 diabetes assessed between 2008-2009 from 18 general practices 13 
in Cambridgeshire and followed up to 2009-2011. The second cohort comprises 1,121 14 
patients with type 2 diabetes from post-trial follow-up data, recruited between 2011-2012 and 15 
followed up to 2015. The SBP was measured at baseline.  Inpatient payments for CVD 16 
hospitalization within 2 years since baseline was the main outcome. The impact of 1:1, group 17 
or combined diabetes peer support and usual care were investigated in the second cohort. 18 
Adjusted mean CVD inpatient payments per person were estimated using a two-part model 19 
after adjusting for baseline characteristics. 20 
 21 
Results 22 
A `hockey-stick’ relationship between baseline SBP and estimated CVD inpatient payment 23 
was identified in both two cohorts, with a threshold at 133-141 mmHg, suggesting increased 24 
payments for patients with SBP below and above the threshold. The combined peer-support 25 
intervention altered the above association, with no increased payment with SBP above the 26 
threshold, and payment slightly decreased with SBP beyond the threshold. 27 
 28 
Conclusion 29 
SBP maintained between 133-141 mmHg is associated with the lowest CVD disease 30 
management costs for patients with Type 2 diabetes. Combined peer-support intervention 31 
could significantly decrease CVD related hospital payments. 32 
 33 
 34 
 35 
INTRODUCTION 36 
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The rapid increase in prevalence and health costs associated with type 2 diabetes has been 37 
observed worldwide 1. It has been estimated that the risk of hospitalisation is two-fold higher 38 
in people with diabetes compared to those without diabetes, and the proportion with diabetes 39 
is >10% in those admitted to hospital at any one time 2. Among some specific age-strata, the 40 
proportion is over 20% 3. The associated costs of excess admissions, as well as increased 41 
costs per admission, are significant contributors to the financial burden borne by healthcare 42 
systems from diabetes and often reflect preventable morbidity suffered by patients 4.  43 
Systolic blood pressure (SBP), as the most common modifiable risk factor, has been found 44 
to be associated both with cardiovascular diseases (CVD) mortality and CVD hospitalisation 45 
among people with type 2 diabetes 5, 6. However, no established association between SBP 46 
and inpatient cost due to CVD hospitalisation has been shown among people with type 2 47 
diabetes. Although a target SBP has been agreed to lower the risk of eg CVD mortality and 48 
CVD hospitalisation, it is unclear whether this threshold will potential impact on inpatient 49 
costs due to CVD mortality. 50 
Diabetes peer support involves people with diabetes assisting each other to improve their 51 
social, mental and physical wellbeing.  Peer support can be provided through individual or 52 
group approaches and either face-to-face, telephone or online contact.   It is generally seen 53 
as a low-cost intervention has been suggested to reduce health-care costs 7.   Some studies 54 
have reported that peer support can reduce health-care costs among people with type 2 55 
diabetes 8, 9.  The RAndomised controlled trial of Peer Support In type 2 Diabetes (RAPSID) 56 
was the largest randomised controlled trial (RCT) of type 2 diabetes peer support to date 10.  57 
The intervention was recently shown to be cost-effective during the trial based on self-58 
reported costs 11 and also from prospective hospital costs [12].  In RAPSID, group peer 59 
support was associated with 2-3 mm Hg lower SBP, however, it was unclear whether this 60 
was a mediator in the reduction in inpatient costs, and whether this was through an effect on 61 
CVD hospitalisation specifically. 62 
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In this study, we aimed to investigate the association between SBP measured in primary 63 
care settings and inpatient cost for CVD hospitalisation over the next 2 years accounting for 64 
the risk of hospitalisation among people with type 2 diabetes, using data from two cohorts. 65 
We have then examined the impact of peer support on this association. 66 
MATERIAL AND METHODS 67 
Data source and study population 68 
 We followed the methods of Dahai Yu et al. 2018 for the data and data collection 12. Briefly 69 
we utilised two cohorts from Cambridgeshire, England: one (main cohort) based on the 70 
electronic health record data from primary care settings to develop our CVD hospitalisation 71 
and re-hospitalisation risk scores and another (replication cohort) based on post-trial cohort 72 
data for external validation.  73 
Main cohort 74 
Patient lists from 18 general practices across Cambridgeshire, England, in 2008/2009 were 75 
collated and linked with hospital admissions (Secondary Uses Service) data as part of an 76 
evaluation of diabetes care across the county by the local health board, National Health 77 
Service (NHS) Cambridgeshire. This cohort was limited to volunteer practices using the 78 
Egton Medical Information Systems general practitioner software system, from which a 79 
predefined set of data could be extracted. There was no systematic selection process for 80 
these surgeries, and data extracted were for their entire diabetes population. All patients with 81 
diabetes had follow-up hospitalisation data to 2010–2011. Hospital admissions to NHS and 82 
private hospitals within and outside Cambridgeshire were followed-up. No personal 83 
identifiers were released to researchers, and all subsequent analyses were conducted on 84 
anonymised datasets. Baseline blood pressure and clinical measurements were recorded as 85 
part of clinical practice in primary care settings6. 86 
  87 
 88 
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Replication cohort 89 
The design and methods of the RAPSID trial have been published previously 10, as have its 90 
Consolidated Standards of Reporting Trials diagram and the results of its primary outcomes 91 
10
.  Briefly, RAPSID was a 2x2 factorial cluster RCT comparing 4 groups: Controls, 1:1 92 
(individual) peer support, group peer support, and combined 1:1 and group peer support 93 
among patients with type 2 diabetes. Participants had their diabetes for at least 12 months 94 
and those with dementia or psychotic illness were excluded. Participants were recruited from 95 
communities across Cambridgeshire and neighbouring areas of Essex and Hertfordshire.  96 
Follow up data were only available for participants in Cambridgeshire and neighbouring 97 
areas of Hertfordshire that are served by the Cambridgeshire and Peterborough Clinical 98 
Commissioning Group (CCG). Clusters were defined by local government (‘parish council’) 99 
boundaries.  The intervention was developed following a pilot, using a framework defined by 100 
Peers for Progress 11.  Peers facilitating peer support were termed peer support facilitators 101 
and their selection, training, support and the overall programme are described elsewhere 10.      102 
The intervention lasted 8-12 months and was commenced and concluded, cluster by cluster, 103 
between 02/06/11 to 12/04/12.  Ethics approval was received from the Cambridgeshire 104 
REC2 Committee (10/H0308/72), and signed consent included agreement for access to 105 
hospital data.   106 
Demographic data, blood pressure, and HbA1c and lipid profiles information were collected 107 
at baseline. Blood pressure were measured using the Omron 705IT Electronic BP Monitor 13. 108 
Each participant was followed up until June 2015 (0.91-4.07 years’ follow-up from 109 
beginning/entry into the trial).  Hospitalisation (NHS hospitals & private hospitals), Accident & 110 
Emergency and outpatient visits within/outside Cambridgeshire and the included areas of 111 
Hertfordshire were collected through Cambridgeshire and Peterborough Clinical CCG 14 as 112 
well as elective/non-elective status, and International Classification of Diseases (ICD-10) 113 
codes15.  114 
Ethical approval 115 
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Ethics approval was received from the Cambridgeshire REC2 Committee (10/H0308/72), 116 
and signed consent included agreement for access to hospital data.   117 
Defining CVD hospitalisation  118 
The primary outcome of the study was having at least one hospitalisation with CVD as the 119 
primary diagnosis (ICD-10: I20–I25, I60–I69 and I73 in the first ICD field) over the 2-year 120 
follow-up.  121 
 122 
Statistical Analysis 123 
A large proportion of the population do not attend hospital as an inpatient or outpatient in 124 
any given year and therefore health care payment data demonstrate a skewed 125 
utilisation/payment pattern 16. To take into account the problem of ‘zero mass’ and skewed 126 
outcomes, the demand functions were modelled using a two-part model 17. In this two-part 127 
model, a probit model was estimated for the probability of observing “zero” versus positive 128 
medical expenditure. Positive medical expenditure is defined as any healthcare expenditure 129 
greater than zero. A generalized linear model (GLM) was estimated, conditional on having 130 
healthcare expenditure. GLM was used, instead of log ordinary least squares regression, 131 
since it relaxes the normality and homoscedasticity assumption, and avoids bias associated 132 
with re-transforming to the raw scale 18. The results of the modified Park test verified that the 133 
use of a gamma distribution, with a log link, was the best fitted GLM for consistent estimation 134 
of coefficients 19. The variance inflation factor (VIF) for all predictors used in the two-part 135 
model indicated no-existence of multi-collinearity 20. The F-test for the two-part regression 136 
models was found to be significant, which indicated the overall significance of the regression 137 
model. Predicted inpatient cost was estimated in the two-part model by the level of baseline 138 
SBP with adjustment of other co-variables. Confidence intervals (95% CI) for estimated 139 
payments were estimated by a bootstrap process with 1000 samples.  Analysis restricted 140 
analyses in each financial year were carried out as sensitivity analyses. All analyses were 141 
performed with STATA (STATA/SE 14.0 StataCorp Texas). 142 
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 143 
 144 
RESULTS 145 
 146 
In our main cohort, we analysed information on 4,704 type 2 diabetes patients with 588 CVD 147 
hospitalisations within 2 years. Our replication cohort had information on 1,121 type 2 148 
diabetes patients with 183 CVD hospitalisations. Table-1 summarises the basic 149 
characteristics and clinical measurements of the study population. Patients with type 2 150 
diabetes in both cohorts had similar age, gender, blood pressure and total cholesterol. 151 
Patients in the main cohort had a higher level of high density lipoprotein, low density 152 
lipoprotein, and HbA1c. Compared with the main cohort, those in the replication cohort were 153 
more likely to be prescribed lowering lipid medicine. Baseline data for the 4 groups of the 154 
replication cohort were well matched (Table-1).  The sample size of the cohort and 155 
intervention groups, characteristics of participants and median cost by baseline systolic 156 
blood pressure categories: <120, 120-129, 130-139, 140-149, 150-159, and >160 mmHg are 157 
presented in Table-2. 158 
As shown in Supplemental Table-1, inpatient cost data from CVD hospitalisation were 159 
typically skewed due to the mass of ‘zero’ payments and a relatively small proportion of 160 
patients incurring extremely high expenditure. 87.5% and 83.7% of participants in the main 161 
and replication cohort were not hospitalised due to CVD diseases over the two year of 162 
follow-up. Within the replication cohort, 79.7% of controls and 82.8%, 85.4% and 86.8% of 163 
patients in the 1:1 group, and combined intervention groups respectively were not 164 
hospitalised due to CVD disease. Among patients hospitalised due to CVD diseases, median 165 
inpatient costs were £4348.35 (IQR: 1623.50 to 8766.75) and £2430.72 (IQR: 793.06 to 166 
4026.20) for the main and replication cohort, respectively. With the replication cohort, 167 
median inpatient costs were £2419.60 (1006.91 to 4387.66), £2489.40 (770.69 to 4387.66), 168 
£1963.56 (714.93 to 4032.55) and £2436.00 (885.19 to 3473.12) for control, 1:1, group and 169 
combined intervention groups, respectively. Compared with patients with no inpatient costs 170 
due to cardiovascular diseases hospitalization, patients with such costs were more likely to 171 
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be older, male, have higher systolic blood pressure, body mass index, and HbA1c, with a 172 
lower proportion were prescribed lipid lowering treatment (Supplemental Table-2). 173 
 174 
Results from two-part model 175 
Dose-response relationship curves between SBP and predicted inpatient cost for CVD 176 
hospitalisation derived from the two-part models after accounting for the risk of CVD 177 
hospitalisation with adjustment of co-variables in Table-1 are presented in Figure-1 for the 178 
main cohort and the replication cohort. SBP was non-linearly associated with adjusted 179 
predicted inpatient cost for CVD hospitalisation (linearity test: all P < 0.00001) both in the 180 
main and replication cohort. The threshold was estimated at 137 (133-141) mmHg for SBP 181 
both in the main sample and replication sample, with consistent stable adjusted predicted 182 
inpatient cost for CVD hospitalisation below the threshold and increased predicted inpatient 183 
cost above the threshold.  184 
 Within the replication cohort, dose-response relationship curves between SBP and adjusted 185 
predicted inpatient cost for CVD hospitalisation in each group is presented in Figure-2. A 186 
non-linear association between SBP and adjusted predicted inpatient cost was found in 187 
control, 1:1 and group intervention groups (linearity test: all P < 0.00001). The threshold at 188 
137 (133-141) mmHg for SBP was consistently found in each group, with consistent stable 189 
adjusted predicted inpatient cost for CVD hospitalisation below the threshold and increased 190 
predicted inpatient cost above the threshold. In the combined intervention group, the 191 
adjusted predicted inpatient cost was linearly stable as SBP increased (linearity test: 192 
P=0.05263). Associations between baseline systolic blood pressure and predicted inpatient 193 
cost due to cardiovascular diseases hospitalisation in those receiving 1:1 peer support and 194 
among the rest within the replication cohort are presented in Supplemental Figure 1. In 195 
each baseline systolic blood pressure level, patients who received the 1:1 peer support 196 
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intervention (as 1:1 alone or as the combined intervention) were more likely to have lower 197 
inpatient costs due to cardiovascular diseases hospitalisation. 198 
 199 
DISCUSSION 200 
 201 
In this study, using two prospective cohorts, we found a non-linear association between SBP 202 
measured in UK populations with type 2 diabetes and the adjusted predicted inpatient cost 203 
for CVD hospitalization over 2 years of follow-up, after accounting for the risk of CVD 204 
hospitalisation both in the main and replication cohort. Further investigation revealed: SBP 205 
below 137 mmHg was associated with stable lowest inpatient cost; inpatient cost increased 206 
with an increase in SBP above 137 mmHg. The peer support intervention, especially group 207 
intervention combined with 1:1 support had a significant impact on the association between 208 
inpatient cost for CVD hospitalisation and SBP. 209 
 210 
Comparison with previous studies 211 
It is well established that SBP is the major determinant of CVD risk in the population who are 212 
aged over 50 21. In patients with type 2 diabetes, previous studies have revealed a J-shape 213 
relationship between SBP and CVD event risk, for example, the United Kingdom Prospective 214 
Diabetes Study 22 showed a lowered CVD event rate with an attained lower BP goal of 215 
144/82 mm Hg.  The International Verapamil SR—Trandolapril 23 and the Avoiding CVD 216 
Events in Combination Therapy in Patients Living with Systolic Hypertension 24 trials also 217 
failed to demonstrate a CVD outcome benefit at a blood pressure below 130/80 mm Hg. We 218 
have previously shown that an SBP between 133-141 mmHg was associated with the lowest 219 
risk of CVD hospitalisation among patients with type 2 diabetes 6. However, it was not clear 220 
whether this J-shape relationship exists between SBP and inpatient costs for CVD 221 
hospitalisation as most studies analysed health cost/payments which had a skewed 222 
distribution Ours is the first study among patients with T2DM, following adjustment for the 223 
individual probability of being hospitalised, and we now show that there is a `hockey-stick’ 224 
shape relationship between SBP and CVD inpatient payment.  This finding suggests that 225 
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CVD inpatient payments are stable for SBP below 133-141 mmHg and linearly increase 226 
above this range.  This in turn supports a SBP target between 133-141 mmHg to minimise 227 
future risks of CVD hospitalisation and associated inpatient payments. 228 
Although we have shown that CVD hospital payments increase with a baseline SBP above 229 
133-144 mm Hg, this was not found to occur in the 2-year post-trial period of RAPSID 230 
intervention participants.  In RAPSID, group peer support was associated with a significant 231 
reduction in SBP after 8-12 month follow-up from baseline and we speculate that it was this 232 
lower SBP that was responsible for this finding.  Hospitalisation was shown to be reduced in 233 
Hong Kong with peer support among those who had high diabetes distress 25.  We have not 234 
been able to elucidate the mechanism behind the lower SBP in RAPSID and have excluded 235 
a greater effect among those with high diabetes distress and medication adherence.  There 236 
was also no evidence of changes in lifestyle as measured by questionnaires, or crudely by 237 
body weight (a small reduction in waist circumference was found in the per protocol 238 
analyses).   The current finding of reduced CVD hospitalisation costs does provide some 239 
validity that the lower SBP described was not simply due to chance. 240 
 241 
This suggests that the peer support intervention was associated with a  reduced inpatient 242 
payment, however in the 2-year post-trial follow-up, among patients in the combined 243 
intervention group, CVD inpatient payment did not increased along with the increase of SBP, 244 
especially beyond 133-141 mmHg, the slightly reduction in the CVD inpatient payment, 245 
suggesting that patients whose SBP beyond 133-141 mmHg were less likely to trigger the 246 
CVD hospitalisation that primarily due to the combined peer-support intervention. The 247 
potential mechanism could be that patients in the combined intervention might stick to the 248 
healthy lifestyle in the post-trial follow-up, which might have an impact on patients’ obesity 249 
status and then SBP as observed in the trial follow-up. However, there was no post-trial 250 
measurements on obesity measurements to prove this hypothesis. Although in the trial 251 
follow-up the SBP reduction could not be explained by increased medication adherence as 252 
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this as previously found to be unchanged [27,28], it was unclear whether anti-hypertensive 253 
treatments adherence pattern was modified in the post-trial follow-up restricted by the post-254 
trial information on the medication adherence.  255 
 256 
Strength and limitation 257 
Strengths of the analysis include that the association between SBP and CVD inpatient 258 
payment was examined in two independent cohorts. A further strength is the minimal 259 
information bias, with the outcome used, recorded inpatient payments, having been fully 260 
recorded by the CCG 26. In particular, as these are payment details, both NHS hospitals and 261 
private hospital admissions were able to be included.   There would have been some loss for 262 
patients where no component of care was paid for by the CCG.   263 
Some limitations have to be considered in the interpretation of our findings.  Unlike 264 
pharmaceutical interventions, where adherence can be assessed using pill counters, it is 265 
difficult to evaluate the magnitude of peer-support intervention on an individual level, and 266 
although we did record attendance and telephone calls, we did not assess engagement.  267 
The payment/savings from similar peer-support interventions should be further investigated 268 
in other post-trial observation studies. Another limitation in this study is the inconsistent 269 
blood pressure measuring methods between primary care recorded blood pressure 270 
measurements (main cohort) and the blood pressure measurement in the trial (replication 271 
cohort), in terms of attended or unattended, standardized protocol vs usual measurement, 272 
automated vs mercury sphygmomanometer. A further limitation of our study is that we have 273 
not been able to describe the activities of participants after the trial was completed.  All 274 
participants were sent the results, and we are aware that some intervention (e.g. peer 275 
support groups) continued including with support from the Diabetes UK “Type 2 Together” 276 
programme 11.  277 
 278 
CONCLUSION 279 
Jo
urn
al 
Pr
e-p
roo
f
 11 
 
As far as we are aware, our study is the first study to examine the prospective association 280 
between SBP and 2-year estimated CVD inpatient payment. A `hockey-stick’ relationship 281 
between SBP and 2-year estimated CVD inpatient payment was identified in two 282 
independent cohorts, with a consistent threshold at 133-141 mmHg and a linearly increased 283 
payment beyond the threshold. Alteration in this relationship following a combined peer-284 
support intervention (group and 1:1 interventions) is suggested by their lack of an increase in 285 
estimated CVD payment. Our findings suggest that among people with type 2 diabetes, 286 
blood pressure management should target a SBP of 133-141 mmHg.  Integration of this 287 
threshold into clinical practice guidance, could lower both individual risk of, and associated 288 
payments for, CVD hospitalisation.  289 
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TABLES AND FIGURE LEGENDS 401 
 402 
Table-1. Baseline Characteristics of study cohorts 403 
  
Main cohort 
 
Replication cohort 
All Control 1:1 Group Combined 
N 4,702 1,121 291 261 288 281 
Cardiovascular diseases 
hospitalisation, n (%) 588 (12.5) 183 (16.3) 59 (20.3) 45 (17.2) 42 (14.6) 37 (13.2) 
Age, years 65.0±16.3 65.5±11.4 65.9±12.8 65.3±9.8 65.8±11.9 65.0±10.4 
Female, n (%) 1,919 (40.8) 444 (39.6) 122 (41.9) 109 (41.8) 101 (35.1) 112 (39.9) 
Systolic blood pressure, mmHg 134.5±16.0 
139.7±20.
2 
140.0±20.
6 
140.4±20.
6 
140.8±19.
5 
137.9±20.
3 
Diastolic blood pressure, mmHg 76.3±10.0 75.5±11.5 75.0±11.6 75.8±10.9 75.1±11.3 75.6±11.9 
Total cholesterol, mmol/L 4.3±1.2 4.2±1.7 4.3±1.5 4.3±1.3 4.1±2.0 4.3±1.7 
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High density lipoprotein, mmol/L 1.3±0.6 1.1±1.2 1.2±0.9 1.2±1.0 1.0±1.5 1.1±1.1 
Low density lipoprotein, mmol/L 2.5±1.4 1.4±3.0 1.3±3.2 1.5±2.8 1.5±2.8 1.5±3.0 
Body mass index, kg/m2 30.8±6.9 32.2±6.0 32.3±6.0 32.6±6.5 32.0±5.9 32.2±5.9 
HbA1c, mmol/mol 61.5±17.2 56.2±15.1 55.6±16.2 56.5±15.0 57.3±14.7 55.3±13.8 
Lipid Lowering treatment, n (%) 3,342 (71.4) 731 (65.2) 180 (61.9) 173 (66.3) 191 (66.3) 187 (66.6) 
 404 
 405 
 406 
 407 
 408 
 409 
 410 
 411 
 412 
 413 
 414 
 415 
 416 
 417 
 418 
 419 
Table-2.  Distribution of baseline characteristics and inpatient cost due to 420 
cardiovascular diseases hospitalization in study cohorts 421 
 422 
 Category of systolic blood pressure, mmHg 
 <120 
mmHg 
120-129 
mmHg 
130-139 
mmHg 
140-149 
mmHg 
150-159 
mmHg 
≥160 
mmHg 
Main Cohort 564 795 1204 1059 324 756 
Replication cohort, overall 134 (12.0) 174 (15.5) 244 (21.8) 255 (22.8) 167 (14.9) 147 (13.1) 
Replication cohort, control 35 (11.9) 46 (15.8) 64 (22.1) 68 (23.5) 46 (15.8) 32 (10.9) 
Replication cohort, group  33 (12.5) 35 (13.6) 50 (19.1) 66 (25.4) 35 (13.6) 41 (15.8) 
Replication cohort, 1:1 30 (10.5) 43 (15.0) 67 (23.3) 62 (21.6) 43 (15.0) 42 (14.6) 
Replication cohort, 
combined 37 (13.0) 50 (17.7) 63 (22.4) 58 (20.6) 43 (15.2) 31 (11.2) 
Age, years 59.9±18.0 62.7±15.8 65.1±14.0 67.7±12.9 68.6±13.2 65.7±19.2 
Female, n (%) 244 (35.0) 382 (39.4) 611 (42.2) 572 (43.5) 208 (42.3) 347 (38.4) 
Systolic blood pressure, 
mmHg 110.3±8.3 123.8±3.1 133.7±3.1 143.0±3.0 153.4±3.1 169.4±10.9 
Diastolic blood pressure, 
mmHg 68.0±9.2 73.4±8.4 76.0±8.3 78.5±8.7 81.2±9.5 85.0±11.3 
Total cholesterol, mmol/L 4.2±1.2 4.2±1.1 4.3±1.1 4.3±1.2 4.5±1.2 4.6±1.3 
High density lipoprotein, 
mmol/L 1.3±0.5 1.2±0.4 1.3±0.5 1.3±0.5 1.3±0.5 1.3±0.5 
Low density lipoprotein, 
mmol/L 2.4±1.0 2.4±1.0 2.5±1.0 2.5±1.0 2.5±1.0 2.6±1.0 
Body mass index, kg/m2 29.8±6.3 30.5±6.7 31.5±6.9 31.5±6.6 31.7±6.4 30.4±7.3 
HbA1c, mmol/mol 61.5±19.5 60.2±16.9 60.9±15.6 60.5±16.0 61.0±15.8 62.4±16.7 
Lipid Lowering treatment, n 
(%) 459 (65.8) 688 (71.0) 1066 (73.6) 1010 (76.9) 364 (74.2) 484 (53.6) 
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People with zero payment, 
n(%) 602 (11.9) 865 (29.0) 1263 (25.0) 1109 (22.0) 382 (7.6) 832 (16.5) 
Median cost (interquartile 
of cost), £  
among people with non-
zero payment 
2436.37 
(629.40 to 
5277.45) 
2017.75 
(763.53 to 
3561.62) 
1781.41 
(644.42 to 
4931.43) 
2507.73 
(1318.58 to 
4786.15) 
2801.81 
(893.70 to 
4008.91) 
3485.46 
(1362.57 to 
4956.08) 
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Figure-1. Adjusted association between baseline systolic blood pressure and predicted 423 
inpatient cost due to cardiovascular diseases hospitalisation in main cohort and replication 424 
cohort 425 
 426 
Figure-2. Adjusted association between baseline systolic blood pressure and predicted 427 
inpatient cost due to cardiovascular diseases hospitalisation in groups of replication cohort 428 
 429 
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